Investigational drug · Phase 2
rhu-pGSN
Also called: recombinant human gelsolin, Recombinant human plasma gelsolin pre-exposure, Recombinant human plasma gelsolin post-exposure
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acute Respiratory Distress Syndrome, Infections, Decompression Sickness.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
6
Any phase or sponsor naming "rhu-pGSN"
First trial start
2024
Oct 3, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "rhu-pGSN", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Respiratory Distress Syndrome
- Infections
- Decompression Sickness
Approved drugs for the same conditions: Infectious disease and vaccines · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "rhu-pGSN" as an intervention, largest first.
- Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)Pivotal-lookingRecruiting
BioAegis Therapeutics Inc.Industry
NCT05947955 · 600 participants (planned) · Start Oct 3, 2024 · Primary completion Oct 1, 2027
Drug: Rhu-pGSN; normal saline · For: Acute Respiratory Distress Syndrome; Infections
Sites: Los Angeles, California; Augusta, Georgia; Chicago, Illinois · 65 sites in all
BioAegis Therapeutics Inc.Industry
NCT04358406 · 64 participants · Start Jul 30, 2020 · Primary completion May 25, 2021
Drug: Recombinant human plasma gelsolin (Rhu-pGSN) · For: Sars-CoV2
Sites: Timișoara, Romania; Reus, Spain; Tarragona, Spain
Critical Biologics CorporationIndustry
NCT00671307 · 40 participants (planned) · Start Mar 2008 · Primary completion Mar 2010
Drug: rhu-pGelsolin; Placebo · For: Low Gelsolin; Trauma; Infection and 1 more
Sites: Hong Kong, Hong Kong
BioAegis Therapeutics Inc.Industry
NCT06216366 · 36 participants · Start Aug 15, 2025 · Primary completion Sep 30, 2025
Drug: Sodium Chloride 0.9% Inj pre-exposure; Sodium Chloride 0.9% Inj post-exposure and 2 more · For: Decompression Sickness
Sites: Baltimore, Maryland
BioAegis Therapeutics Inc.Industry
NCT03466073 · 33 participants · Start Aug 28, 2018 · Primary completion Apr 2, 2019
Drug: Recombinant Human Plasma Gelsolin · For: Community-acquired Pneumonia
Sites: Cairns, Australia; Box Hill, Australia; Footscray, Australia · 8 sites in all
BioAegis Therapeutics Inc.Industry
NCT05789745 · 32 participants · Start Mar 14, 2023 · Primary completion May 24, 2023
Drug: Recombinant human plasma gelsolin · For: Volunteers; Healthy
Sites: Saint Paul, Minnesota
Newest research
PubMed records naming it or its code names, newest first.
- A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Escalation Study for the Evaluation of the Safety, Tolerability, and Pharmacokinetics of Recombinant Human Plasma Gelsolin (rhu-pGSN) Following Intravenous Administration to Healthy Volunteers.
Liu Y, Levinson SL, Kowalik E, et al. · Clin Pharmacol Drug Dev 2026
- Scalable production of functional recombinant human plasma gelsolin in Escherichia coli for therapeutic and diagnostic applications.
Kim YS, Lee HJ, Kim MR, et al. · Protein Expr Purif 2025
- Antibiotics and non-traditional antimicrobial agents for carbapenem-resistant Acinetobacter baumannii in Phase 1, 2, and 3 clinical trials.
Kontogiannis DS, Romanos LT, Tzvetanova ID, et al. · Expert Opin Investig Drugs 2025
- Recombinant human plasma gelsolin suppresses persistent neuroinflammation and restores hippocampal neurogenesis in murine model of decompression sickness.
Bhat AR, Arya AK, Bhopale VM, et al. · J Neurophysiol 2024
- Is there a renal protective role for gelsolin treatment in crush syndrome? An experimental study.
Acar D, Gülpembe M, Özdamar EN · Ulus Travma Acil Cerrahi Derg 2024
- Adjunctive Recombinant Human Plasma Gelsolin for Severe Coronavirus Disease 2019 Pneumonia.
DiNubile MJ, Parra S, Salomó AC, et al. · Open Forum Infect Dis 2022
Also in development for Acute Respiratory Distress Syndrome
- STSA-1002Phase 32 trials
Staidson (Beijing) Biopharmaceuticals Co., Ltd · Acute Respiratory Distress Syndrome (ARDS), Acute Respiratory Distress Syndrome
- UC-MSCRY_SW01 cell, Human umbilical cord mesenchymal stem cellsPhase 28 trials
Jiangsu Renocell Biotech Company · Acute Respiratory Distress Syndrome, Lupus Nephritis, Spinocerebellar Ataxia Type 1
- AtibuclimabIC14Phase 24 trials
Implicit Bioscience · Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury
- SecretomeConditioned, Umbilical Cord Mesenchymal Stem Cells derived ConditionedPhase 24 trials
PT. Prodia Stem Cell Indonesia · Acute Respiratory Distress Syndrome, Androgenetic Alopecia, Ischemic Stroke
- paridiprubartPhase 22 trials
PPD Development, LP · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)
- vilobelimabPhase 22 trials
PPD Development, LP · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)
- AV-001Phase 21 trial
Vasomune Therapeutics, Inc. · Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.